• 1
    Bessesen DH. Update on obesity. J Clin Endocrinol Metab 2008; 93: 202734.
  • 2
    James WPT. The epidemiology of obesity: the size of the problem. J Intern Med 2008; 263: 33652.
  • 3
    Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 2008; 16: 232330.
  • 4
    World Health Organisation. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Geneva, Tech Rep Ser 2000; 894: 1253.
  • 5
    Tsigos C, Hainer V, Basdevant A, et al. Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1(2): 10616.
  • 6
    Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011; 28: 1792818.
  • 7
    Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; article ID 179674: 118.
  • 8
    Fried M, Ribaric G, Buchwald JN, Svacina S, Dolezalova K, Scopinaro N. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI<35 kg/m2: an integrative review of early studies. Obes Surg 2010; 20: 77690.
  • 9
    Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care 2008; 31(Suppl 2): S26977.
  • 10
    Greaves CJ, Sheppard KE, Abraham C, et al. Systemic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health 2011; 11: 119.
  • 11
    Crandall JP, Knowler WC, Kahn SE, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008; 4(7): 38293.
  • 12
    Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care 2007; 30(2): 395402.
  • 13
    Wadden TA, West DS, Neiberg RH, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity 2009; 17: 71322.
  • 14
    Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wismiewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001; 161: 21827.
  • 15
    Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 211120.
  • 16
    Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65(10): 1391418.
  • 17
    Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404(6778): 66171.
  • 18
    Cota D, Tschöp MH, Horvath TL, Levine AS. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 2006; 51: 85107.
  • 19
    Cota D. The role of endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008; 20: 358.
  • 20
    Rössner S. The trial that killed a drug. Lakartidningen 2010; 107: 2339.
  • 21
    James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363(10): 90517.
  • 22
    Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf 2010; 33(7): 60513.
  • 23
    Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 2010; 34(5): 91935.
  • 24
    Astrup A, Greenway FL, Ling W, et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity (Silver Spring) 2007; 15(7): 171731.
  • 25
    Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008; 83(2): 2817.
  • 26
    Arch JR. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspective from beta3-adrenoreceptor agonists. Naunyn Schmiederbergs Arch Pharmacol 2008; 378: 22540.
  • 27
    Perrone MG, Scilimati A. Beta(3)-adrenoreceptor ligand development history through patent review. Expert Opin Ther Pat 2011; 21: 50536.
  • 28
    Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8: 30820.
  • 29
    Scanlan TS. Soberitome: a case history of bench-to-clinic discovery and development. Heart Fail Rev 2010; 15: 17782.
  • 30
    Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized trials. Int J Obes (Lond) 2002; 26: 26273.
  • 31
    Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 53246.
  • 32
    Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 11949.
  • 33
    O′Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int J Obes Relat Metab Disord 1995; 19: 1819.
  • 34
    James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 211925.
  • 35
    Rössner S, Sjöström L, Noack R, Menders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 4961.
  • 36
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 138997.
  • 37
    Cercato C, Roizenblatt VA, Leanca CC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond) 2009; 33: 85765.
  • 38
    Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006; 47: 61425.
  • 39
    Swinburn BA, Carmichael HE, Wilson MR. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Int J Obes Relat Metab Disord 1996; 20: 103340.
  • 40
    Després J-P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 212134.
  • 41
    Cordero-MacIntyre ZR, Lohman TG, Rosen J, et al. Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. J Am Coll Nutr 2000; 19: 27584.
  • 42
    Willey KA, Molyneaux LM, Yue DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabet Med 1994; 11: 7014.
  • 43
    Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164: 1395404.
  • 44
    Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006; 368: 166072.
  • 45
    Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 15561.
  • 46
    Johansson K, Sundstrom J, Neovius K, Rossner S, Neovius M. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2010; 11: 77791.
  • 47
    Ruilope LM, Després JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008; 26: 35767.
  • 48
    Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 44152.
  • 49
    Jordan J, Schulze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 2005; 29: 50916.
  • 50
    Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007; 3: 81721.
  • 51
    Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq Bras Endocrinol Metabol 2009; 53: 26270.
  • 52
    Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. Int J Obes (Lond) 2005; 29: 20816.
  • 53
    Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials with sibutramine vs. placebo. Am J Manag Care 2001; 7: 87583.
  • 54
    Di Francesco V, Sacco T, Zamboni M, et al. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Ann Nutr Metab 2007; 51: 7581.
  • 55
    Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatment: a systematic review. Int J Obes (Lond) 2008; 32: 175263.
  • 56
    Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes 2007; 31(3): 4949.
  • 57
    Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity 2010; 18(1): 10815.
  • 58
    Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96(10): 306777.
  • 59
    Ornellas T, Chavez B. Naltrexone SR/Bupropion SR (Contrave). A new approach to weight loss in obese adults. PT 2011; 36: 25562.
  • 60
    Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9653): 190613.
  • 61
    Sjödin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond) 2010; 34(11): 163443.
  • 62
    O’Rahilly S, Farooqi IS, Yeo GS, Challis BG. Minireview: human obesity-lessons from monogenic disorders. Endocrinology 2003; 144(9): 375764.
  • 63
    Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115(12): 357986.
  • 64
    Nargund RP, Strack AM, Fong TM. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J Med Chem 2006; 49(14): 403543.
  • 65
    Roubert P, Dubern B, Plas P, et al. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. J Endocrinol 2010; 207(2): 17783.
  • 66
    Wu YK, Yeh CF, Ly TW, Hung MS. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing blood-brain barrier. Curr Top Med Chem 2011; 11: 14219.
  • 67
    Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11: 7988.
  • 68
    Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 221724.
  • 69
    Chao EC. A paradigm shift in diabetes therapy – dapagliflozin and other SGPLT2 inhibitors. Discov Med 2011; 11: 25563.
  • 70
    Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 2010; 122: 217.
  • 71
    Tiwari A. INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes. Drugs 2010; 13: 26675.
  • 72
    Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 2009; 68: 83043.
  • 73
    Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32(5): 7628.
  • 74
    Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32(7): 122430.
  • 75
    Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374(9701): 160616.
  • 76
    Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36(6): 84354.
  • 77
    Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009; 124(1): 4456.
  • 78
    Moran TH, Dailey MJ. Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology 2009; 150(6): 252630.
  • 79
    Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol 2009; 66(3): 30610.
  • 80
    Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother 2010; 44: 53845.
  • 81
    Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31(9): 181623.
  • 82
    Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349(10): 9418.
  • 83
    Gantz I, Erondu N, Mallick N, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metabol 2007; 92: 17547.
  • 84
    Fenske WK, Bueter M, Miras AD, Ghatei MA, Bloom SR, le Roux CW. Exogenous peptide YY3-36 and Exendin-4 further decreased food intake, whereas octreotide increases food intake after Roux-en-Y gastric bypass. Int J Obes (Lond) 2012; 36(3): 37984.
  • 85
    Field BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 16359.
  • 86
    Elliot RL, Cameron KO, Chin JE, et al. Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo-[4,3.a]-[1,5]benzodiazepine-6-yl]-N isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity. Bioorg Med Chem Lett 2010; 20: 6797801.
  • 87
    Egecioglu E, Jerlhag E, Salomé N, et al. Ghrelin increases intake of rewarding food in rodents. Addict Biol 2010; 15(3): 30411.
  • 88
    Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol 2007; 33(2): 17689.
  • 89
    Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 2000; 24(Suppl 2): S805.
  • 90
    Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011; article ID 471584: 110.
  • 91
    Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010; 95: 4291304.
  • 92
    Grunfeld C, Dritselis A, Kirckpatrick P. Tesamorelin. Nat Rev Drug Discov 2011; 10: 956.
  • 93
    Toubro S, Astrup AV, Breum L, Quadde F. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. Int J Obes Relat Metab Disord 1993; 17 (Suppl 1): S6972.
  • 94
    Greenway FL, Bray GA. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract 2008; 14: 697703.
  • 95
    Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51: 58694.
  • 96
    Connoly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenluramine-phentermine. N Engl J Med 1997; 337: 5818.
  • 97
    Morita T, Mehendale HM. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis 1983; 127(6): 74750.
  • 98
    Greenway FL, Fujioka F, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet; 2010; 376: 595605.
  • 99
    Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with Naltrexone SR/Bupropion SR combination as an adjunct to behaviour modification: The COR-BMOD trial. Obesity (Silver Spring) 2011; 19: 11020.
  • 100
    Gadde KM, Allison DB, Ryan DH, et al. Effect of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 134152.
  • 101
    Klein S, Najarian T, Troupin B, Day WW. Weight loss with low-dose, controlled-release phenetermine/topiramate correlates with improvements in liver function in overweight/obese adults with elevated alanine aminotransferase. Obesity (Silver Spring) 2011; 19 (Suppl 1): S177.
  • 102
    Garvey WT, Najarian T, Peterson C. Weight loss with controlled-release phentermine/topiramate is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks. Obesity (Silver Spring) 2011; 19 (Suppl 1): S176.
  • 103
    Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17(9): 173643.
  • 104
    Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010; 18(9): 173946.
  • 105
    Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007; 68: 12269.
  • 106
    Patel SR. Reduced sleep as an obesity risk factor. Obes Rev 2009; 10(Suppl 2): 618.
  • 107
    Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity? Int J Pediatr Obes 2008; 3(Suppl 1): 3743.
  • 108
    Peter JC, Bekel A, Lecourt AC, et al. Anti-melanocortin-4 receptor autoantibodies in obesity. J Clin Endocrinol Metab 2009; 94(3): 793800.
  • 109
    Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444(7122): 102731.
  • 110
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444(7122): 10223.
  • 111
    Willett WC. Balancing life-style and genomics research for disease prevention. Science 2002; 296: 6958.
  • 112
    Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281(3): 23542.
  • 113
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295(7): 76175.
  • 114
    Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 24556.
  • 115
    Dvorak RV, Sharma AM, Astrup A. Antiobesity drugs: to be or not to be? Obes Rev 2010; 11: 8334.